Opendata, web and dolomites

THERADNET SIGNED

International NETwork for training and innovations in THErapeutic RADiation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 THERADNET project word cloud

Explore the words cloud of the THERADNET project. It provides you a very rough idea of what is the project "THERADNET" about.

limiting    critical    understand    hypotheses    adverse    innovations    dampen    standard    outstanding    radiobiological    stimulate    employability    treatment    50    cancer    cured    therapy    dose    tumor    radiobiology    clinical    biological    intrinsic    prior    care    approximately    normal    alone    medicine    students    individual    modalities    translational    cooperate    close    surrounding    metastatic    combined    60    regrowth    training    therapeutic    situation    guarantee    microenvironment    countries    industry    disease    personalized    despite    academia    death    altered    benefit    radiation    collaborations    innovative    co    optimized    substantial    sectors    primary    window    integration    innovation    resistance    patients    recurrence    expertise    tissues    outgrowth    small    radiotherapy    precision    premises    successful    multimodality    health    science    models    performed    improvements    pursuit    plasticity    network    international    integrating    reactions    irradiated    widen    45    outcome    immune    mass    metabolism    biologically    acquired    combatting    community   

Project "THERADNET" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAT ZURICH 

Organization address
address: RAMISTRASSE 71
city: ZURICH
postcode: 8006
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 4˙026˙324 €
 EC max contribution 4˙026˙324 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-ETN
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2023-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAT ZURICH CH (ZURICH) coordinator 562˙553.00
2    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 606˙345.00
3    INSTITUT CURIE FR (PARIS) participant 549˙604.00
4    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) participant 531˙239.00
5    UNIVERSITE CATHOLIQUE DE LOUVAIN BE (LOUVAIN LA NEUVE) participant 512˙640.00
6    TECHNISCHE UNIVERSITAET DRESDEN DE (DRESDEN) participant 505˙576.00
7    UNIVERSITAETSKLINIKUM ESSEN DE (ESSEN) participant 505˙576.00
8    WESTDEUTSCHES PROTONENTHERAPIEZENTRUM ESSEN (WPE) GGMBH DE (ESSEN) participant 252˙788.00

Map

 Project objective

Radiotherapy alone or in multimodality approaches is applied in 45-60% of all cancer patients, but despite technical innovations approximately only 50% are cured. Disease recurrence may be due to regrowth of the primary tumor or metastatic outgrowth. Intrinsic and acquired resistance of the tumor and adverse reactions in the co-irradiated surrounding normal tissues dampen a successful therapy outcome. Substantial improvements are now expected from biologically optimized, personalized radiotherapy. This network is built on the premises that integration of novel-emerging radiobiological and tumor-biological concepts into current standard-of-care will improve outcome of radiotherapy-treated cancer patients. As the field of radiobiology is small in individual countries, it is essential to cooperate on the European level to achieve a critical mass for innovation in research and training. The partners in this network will stimulate outstanding science to understand the plasticity of an altered tumor metabolism and tumor microenvironment, including the immune system, prior to, and in response to radiotherapy, as well as related dose-limiting adverse effects in normal tissues. Research and development of novel combined treatment modalities in these areas will be performed in models as close as possible to the clinical situation to evaluate their potential to widen the therapeutic window beyond standard-of-care. Students will benefit from outstanding expertise and collaborations within academia and industry integrating novel concepts into translational cancer and radiation research. This will guarantee high employability in various sectors of cancer research and precision medicine. The European community will benefit from the pursuit of innovative hypotheses, training of new researchers, and dissemination of knowledge. By combatting a major death-related disease in Europe, this project will raise health and bring long-term benefit to the European and international community.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERADNET" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THERADNET" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

ARCH (2019)

AGE-RELATED CHANGES IN HEMATOPOIESIS

Read More  

PARACAT (2019)

Paramagnetic Species in Catalysis Research. A Unified Approach Towards Heterogeneous, Homogeneous and Enzyme Catalysis

Read More  

CHANGE (2019)

Cultural Heritage Analysis for New GEnerations

Read More